Latest Headlines

Does Anemia Protect Children From Malaria?

It is well known that sickle cell trait can protect carriers from developing malaria; yet iron deficiency anemia offers a greater protective effect against malaria than sickle cell trait, according to research published in...

Online Exclusive

Regional Hospital Consortiums Hope to Compete for Clinical Trials

In a bid to attract research funding while reducing administrative costs, small hospitals across the U.S. are joining together to create clinical trial consortiums....

Precision Therapy Proves Effective, but Costly

Precision medicine, or treatments tailored to individual patients based on genetic testing and other factors, has shown incredible promise in extending the lives of...

Cover Story

Predatory Publishing: The Dark Side of the Open-Access Movement

In October 2016, we dived deep into the open-access (OA) movement – a publishing model in which a scientific article is made freely available – examining the benefits and the drawbacks of this approach to research (“Public Access: The Pros and Cons of Open-Access Publishing”). This month, we take a closer look at another, darker side of scientific publishing: predatory publishing. This segment of the OA publishing movement is characterized by publishers that “unprofessionally exploit” the gold OA model (in which the final version of a manuscript is made freely available on publication), primarily for profit, according to Jeffrey Beall, MSLS, one of the most vigilant watchdogs of predatory publishing, and operator of the website Scholarly Open Access. Sometimes called “vanity presses,” these entities publish practically any materials that come their way, as long as authors are willing to pay a submission and publication fee. Critics – and they are legion...

Clinical News

Latest Videos

Pulling Back the Curtain: Vip Viprakasit, MD, DPhil

In more from our interview with Dr. Viprakasit, he speaks about the advantages of working in a limited-resource setting and the importance of international...

Let’s Get Cooking: Jonathan Hoggatt, PhD

In more from our interview with Dr. Hoggatt, he talks about the chocolate chip cookie experiment that started his obsession with cooking.

Pulling Back the Curtain: Richard W. Childs, MD

Hear more from our interview with Dr. Childs, where he talks about his inventive career in medicine and the best and worst parts of his...

LentiGlobin Gene Therapy Possibly Safe for Severe Sickle Cell Disease

Interim data from a phase I study of LentiGlobin BB305 in patients with severe sickle cell disease (SCD) suggest that the gene therapy was...

On Location

From ASH Meeting on Hematologic Malignancies: Treating Patients With AML With Mutations and Minimal Residual Disease

During their presentations, MHM speakers will be asking the audience how they would respond to...

From ASH Meeting on Hematologic Malignancies: Treating “Problematic” Cases of Polycythemia Vera

During their presentations, MHM speakers will be asking the audience how they would respond to...

From ASH Meeting on Hematologic Malignancies: Treating a Young Patient With Newly Diagnosed ALL

During their presentations, MHM speakers will be asking the audience how they would respond to...

Researchers Define Long-Term Outcomes of Cancer-Associated Thrombosis

Patients diagnosed with cancer-associated thrombosis (CAT) remain at a high risk for recurrent venous thromboembolism...

Romiplostim Helps Patients With Glioblastoma and Thrombocytopenia Stay on Treatment

Temozolomide (TMZ) is part of the standard treatment for patients with glioblastoma, but the drug...

APR-246 Plus Azacitidine Is Associated With High Response Rates in MDS and AML

In a small phase IB/II trial presented at the 23rd Congress of the European Hematology...
Advertisement

Sign Up for our enewsletter!

Subscribe to our newsletter to receive the latest news, updates and online exclusive content.

8,802FollowersFollow
6,346SubscribersSubscribe

Medicare Part D Beneficiaries With Myeloma Receive Novel Therapies More Frequently, Have Better Survival...

People with myeloma who have prescription drug coverage under Medicare are less likely to use older cytotoxic chemotherapy and more likely to receive newly...

Ruxolitinib Plus Azacitidine Improves Survival, Bone Marrow Fibrosis in Myelofibrosis

Adding azacitidine to ruxolitinib led to an “encouraging” spleen and bone marrow fibrosis response rate in patients with myelofibrosis (MF), compared with previous experience...

FDA Approves Powerful Synthetic Opioid

The U.S. Food and Drug Administration (FDA) has approved a new form of the synthetic opioid sufentanil for the management of acute pain in...

CMS Finalizes Physician Fee Schedule for 2019

The Centers for Medicare and Medicaid Services (CMS) has finalized changes to the Medicare Physician Fee Schedule and the Quality Payment Program for 2019,...

Gene Therapy Suppliers Foresee Struggle to Meet Demand

Despite high costs, gene therapy manufacturing has thus far been able to keep pace with demand, but that could change, as treatments for hemophilia...